Edition:
United States

People: Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

282.92USD
21 Jul 2017
Change (% chg)

$1.48 (+0.53%)
Prev Close
$281.44
Open
$280.25
Day's High
$283.00
Day's Low
$280.02
Volume
985,437
Avg. Vol
1,571,161
52-wk High
$333.65
52-wk Low
$244.28

Pangia, Robert 

Mr. Robert W. Pangia is an Independent Director of the Company. Mr. Pangia served as a director of the Company from 1997 to 2003 during the period the Company was operated as IDEC Pharmaceuticals, and has served as a director since 2003 following IDEC’s merger with Biogen Inc. Mr. Pangia has been a partner in Ivy Capital Partners, LLC, the general partner of Ivy Healthcare Capital, L.P., a private equity fund specializing in healthcare investments, since 2003. From 2011 to 2016 he was also the Chief Executive Officer of Ivy Sports Medicine, LLC, a medical device company. From October 2007 to October 2009, he also served as the Chief Executive Officer of Highlands Acquisition Corp., a special purpose acquisition company. From 1996 to 2003, Mr. Pangia was self-employed as an investment banker. From 1987 to 1996, he held various senior management positions at PaineWebber, a financial services company, including Executive Vice President and Director of Investment Banking for PaineWebber Incorporated of New York, a member of the Board of Directors of PaineWebber, Inc., Chairman of PaineWebber Properties, Inc., and a member of several of PaineWebber’s executive and operating committees.

Basic Compensation

Total Annual Compensation, USD 153,000
Restricted Stock Awards, USD 269,420
Long-Term Incentive Plans, USD --
All Other, USD 57,011
Fiscal Year Total, USD 479,431

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --